Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy
Links shared publicly online about this topic.
- 389total visits
Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy
Pfizer Inc. announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).
View full resource at news-medical.net
Tags: Diet and Nutrition, Drug, FDA, Pfizer
Most Recently Shared on April 4, 2011 at 3:03 pm By:
Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy:... http://bit.ly/hqTsvh
Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application
drugs.com — “Tafamidis is a new drug in development for the treatment of Transthyretin Familial Amyloid Polyneuropathy. Tafamidis information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on April 19, 2011 at 4:15 am By:
Drugs and Devices OW OW Health
Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application: NEW YORK--(BUSINES... http://bit.ly/g2M9hN #drug
Advertisement
